Silexion Therapeutics Corp (SLXN): M&A transaction — Silexion closes SPAC merger with Moringa; begins trading on Nasdaq under SLXN

Silexion Therapeutics Corp

9,768,396 New Silexion ordinary shares outstanding post-closing; 87,722 Moringa public shares survived redemptions.
Redemption of 427,297 Moringa shares at ~$11.575 for total ~$4.95M from trust account.
Raised $2M via PIPE at $10/share from Greenstar LP; secured up to $15M ELOC with White Lion Capital.
Issued $1.25M convertible note to EarlyBird (6% interest, due 2025) plus $3.433M sponsor promissory note.
Adopted 2024 Equity Incentive Plan; lock-ups for insiders with 6-month cliff and potential $12 price trigger.

item 1.01 item 5.02 item 2.01 item 5.06 item 3.02 item 5.03 item 2.03 item 3.03 item 5.01 item 5.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Silexion Therapeutics Corp underwent a change of control involving Moringa Acquisition Corp, Silexion Therapeutics Ltd. (closed 2024-08-15).

Action: change of control
Counterparty: Moringa Acquisition Corp, Silexion Therapeutics Ltd.
Closing: 2024-08-15

Exact text from the filing

On August 15, 2024 (the "Closing Date"), Silexion Therapeutics Corp (formerly known as Biomotion Sciences), a Cayman Islands exempted company (the "registrant") consummated the previously announced transactions pursuant to that certain Amended and Restated Business Combination Agreement, dated as of April 3, 2024 (as amended, the "Business Combination Agreement"), by and among the registrant, Moringa Acquisition Corp ("Moringa"), August M.S. Ltd., an Israeli company and a wholly-owned subsidiary of the registrant ("Merger Sub 1"), Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and a wholly-owned subsidiary of the registrant ("Merger Sub 2"), and Silexion Therapeutics Ltd., an Israeli company ("Silexion").

View on SEC.gov

21 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-071491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.